Neos Therapeutics (NEOS) Posts Wider-than-Expected Q3 Loss

Neos Therapeutics (NASDAQ: NEOS) reported Q3 EPS of ($0.77), $0.19 worse than the analyst estimate of ($0.58). Revenue for the quarter came in at $221 thousand versus the consensus estimate of $800 thousand.

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Paysafe Limited (PSFE) Misses Q2 EPS by 43c; offers guidance
• SBC Medical Group Holdings Incorporated (SBC) Misses Q2 EPS by 2c
• X-Energy, Inc. (XE) Reports Q2 Loss of $0.15